Replies to post #167010 on Biotech Values

[DewDiligence]

SYK/MAKO—Agreed [that there is no technical synergy], but there is clearly marketing synergy.

Some, but not that much, IMO. SYK’s knees are marketed almost exclusively to individual orthopedists, while the MAKO system is marketed largely to hospitals and clinics. From MAKO’s 10-K (http://www.sec.gov/Archives/edgar/data/1411861/000089710113000266/mako130784_10k.htm ):

Our strategy is to convince hospitals that through early adoption of MAKOplasty and acquisition of our RIO system, they can improve their clinical outcomes and, as a result, reinforce their reputations as leading institutions for the treatment of osteoarthritic disease.